

Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle

Authorised

- Framycetin sulfate
- Benethamine penicillin
- Penethamate hydriodide

Product identification

Medicine name:

Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle

Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle

Active substance:

Framycetin sulfate

Benethamine penicillin

Penethamate hydriodide

Target species:

Cattle

Route of administration:

Intramammary use

Product details

Active substance and strength:

Framycetin sulfate

100.00 milligram(s) / 1.00 Syringe

Benethamine penicillin

280.00 milligram(s) / 1.00 Syringe

Penethamate hydriodide

100.00 milligram(s) / 1.00 Syringe

Pharmaceutical form:

Intramammary suspension

Withdrawal period by route of administration:

Intramammary use:

-

Cattle

- Meat and offal. 10 day

- Milk. 37 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ51RC25

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Ireland

Package description:

Cardboard box or plastic container containing 20 single use intramammary syringes and 20 teat wipes (containing isopropanol 70%). Each 4.5 g syringe (cylinder with piston and cap, all made of low density polyethylene) contains 5 ml intramammary

suspension.

Cardboard box or plastic container containing 60 single use intramammary syringes and 60 teat wipes (containing isopropanol 70%). Each 4.5 g syringe (cylinder with piston and cap, all made of low density polyethylene) contains 5 ml intramammary suspension.

Cardboard box or plastic container containing 120 single use intramammary syringes and 120 teat wipes (containing isopropanol 70%). Each 4.5 g syringe (cylinder with piston and cap, all made of low density polyethylene) contains 5 ml intramammary suspension.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:

23/11/2012

Manufacturing sites for batch release:

Lohmann Pharma Herstellung GmbH

Haupt Pharma Latina S.r.l.

Responsible authority:

Health Products Regulatory Authority

Authorisation number:

VPA10454/001/001

Date of authorisation status change:

23/11/2012

Reference member state:

Ireland

Procedure number:

IE/V/0271/001

Concerned member states:

Belgium Bulgaria Czechia France Hungary Netherlands Poland Romania
Slovakia Slovenia United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics